MetaCap

Standard BioTools (LAB) vs Precipio (PRPO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Precipio (PRPO) has outperformed Standard BioTools (LAB) over the past year, losing 29.2% versus a loss of 54.3%. Over five years, PRPO leads with a -54.6% price change compared with -86.5% for LAB. Standard BioTools is the larger company by market cap ($249.1 million vs $31.1 million), about 8.0 times the size, while Precipio is growing revenue faster (+29.8% vs -6.2%).

Precipio converts more of its revenue into profit, with a net margin of -1.5% versus -87.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LAB-54.28%PRPO-29.18%
+37%-14%-66%
Nov 21, 20251 yearNov 20, 2026
LAB-85.95%PRPO-55.74%
+9%-42%-93%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LAB versus PRPO key metrics
MetricLABPRPO
Share price$0.631$17.35
Market cap$249.11M$31.11M
1-day change+2.82%-6.17%
YTD return-50.70%-24.50%
1-year return-54.28%-29.18%
5-year return-86.55%-54.58%
Forward P/E—44.49
EPS (TTM)$-0.09$-0.59
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$85.33M$24.05M
Revenue growth (YoY)-6.24%+29.77%
Net income (latest FY)$-74.90M$-363.00K
Gross margin49.86%44.52%
Operating margin-129.20%-5.00%
Net margin-87.77%-1.51%
52-week high$1.72$33.63
52-week low$0.39$17.30
Distance from 52-week high-63.31%-48.41%
Analyst consensusnone—
Avg. price target upside+113.95%—
Average volume1.16M79.50K
Shares outstanding394.79M1.79M
Employees38561
SectorIndustrialsIndustrials
IndustryBiotechnology: Laboratory Analytical InstrumentsBiotechnology: Laboratory Analytical Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Standard BioTools is about 8.0 times larger than Precipio by market value ($249.11M vs $31.11M).
  • PRPO has outperformed LAB by 25.1 percentage points over the past year.
  • Precipio is more profitable, keeping -1.5 cents of every revenue dollar as net income versus -87.8 cents for Standard BioTools.
  • Precipio grew revenue faster in its latest fiscal year (+29.77% vs -6.24%).

About Standard BioTools

LAB stock →

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments.

Industrials · Biotechnology: Laboratory Analytical Instruments · 385 employees

About Precipio

PRPO stock →

Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services.

Industrials · Biotechnology: Laboratory Analytical Instruments · 61 employees

LAB vs PRPO FAQ

Which is bigger, Standard BioTools or Precipio?

Standard BioTools (LAB) is larger, with a market capitalization of $249.11M compared with $31.11M for Precipio (PRPO).

Which stock has performed better over the past year, LAB or PRPO?

PRPO returned -29.18% over the past 12 months, compared with -54.28% for LAB (price return, excluding dividends). Past performance does not predict future results.

Are Standard BioTools and Precipio in the same industry?

Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.

More comparisons